JP2006524250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524250A5 JP2006524250A5 JP2006513138A JP2006513138A JP2006524250A5 JP 2006524250 A5 JP2006524250 A5 JP 2006524250A5 JP 2006513138 A JP2006513138 A JP 2006513138A JP 2006513138 A JP2006513138 A JP 2006513138A JP 2006524250 A5 JP2006524250 A5 JP 2006524250A5
- Authority
- JP
- Japan
- Prior art keywords
- fatty acid
- acid analog
- tissue
- radiolabeled fatty
- radiolabeled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000014113 dietary fatty acids Nutrition 0.000 claims 80
- 229930195729 fatty acid Natural products 0.000 claims 80
- 239000000194 fatty acid Substances 0.000 claims 80
- 150000004665 fatty acids Chemical class 0.000 claims 79
- 210000001519 tissue Anatomy 0.000 claims 59
- 239000000203 mixture Substances 0.000 claims 39
- 125000001424 substituent group Chemical group 0.000 claims 18
- 239000002207 metabolite Substances 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 238000000034 method Methods 0.000 claims 12
- 125000004122 cyclic group Chemical group 0.000 claims 11
- 230000000717 retained effect Effects 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 210000005003 heart tissue Anatomy 0.000 claims 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 239000007858 starting material Substances 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 150000001924 cycloalkanes Chemical group 0.000 claims 4
- 229910052738 indium Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000003138 primary alcohols Chemical class 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 238000006356 dehydrogenation reaction Methods 0.000 claims 3
- 230000008030 elimination Effects 0.000 claims 3
- 238000003379 elimination reaction Methods 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- -1 ketoacetyl Chemical group 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 238000009792 diffusion process Methods 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 230000033444 hydroxylation Effects 0.000 claims 2
- 238000005805 hydroxylation reaction Methods 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 239000000700 radioactive tracer Substances 0.000 claims 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims 2
- 235000009518 sodium iodide Nutrition 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 229910052724 xenon Inorganic materials 0.000 claims 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims 2
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 206010056375 Bile duct obstruction Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 208000019399 Colonic disease Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 206010053990 Dacryostenosis acquired Diseases 0.000 claims 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000013612 Parathyroid disease Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000026375 Salivary gland disease Diseases 0.000 claims 1
- 208000019229 Spleen disease Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 229930003779 Vitamin B12 Natural products 0.000 claims 1
- 206010000059 abdominal discomfort Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000029162 bladder disease Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 208000015322 bone marrow disease Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000011666 cyanocobalamin Substances 0.000 claims 1
- 229960002104 cyanocobalamin Drugs 0.000 claims 1
- AZSFNUJOCKMOGB-UHFFFAOYSA-K cyclotriphosphate(3-) Chemical compound [O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 AZSFNUJOCKMOGB-UHFFFAOYSA-K 0.000 claims 1
- 125000005442 diisocyanate group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 125000005313 fatty acid group Chemical class 0.000 claims 1
- 239000011640 ferrous citrate Substances 0.000 claims 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims 1
- 229960001731 gluceptate Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 208000015210 hypertensive heart disease Diseases 0.000 claims 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 229910052743 krypton Inorganic materials 0.000 claims 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 claims 1
- 208000000617 lacrimal duct obstruction Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 229940058213 medronate Drugs 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000037323 metabolic rate Effects 0.000 claims 1
- FFEARJCKVFRZRR-JJZBXVGDSA-N methionine c-11 Chemical compound [11CH3]SCC[C@H](N)C(O)=O FFEARJCKVFRZRR-JJZBXVGDSA-N 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 229960003540 oxyquinoline Drugs 0.000 claims 1
- 208000022560 parathyroid gland disease Diseases 0.000 claims 1
- 229940067082 pentetate Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 235000021317 phosphate Nutrition 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 229910052701 rubidium Inorganic materials 0.000 claims 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000009738 saturating Methods 0.000 claims 1
- 239000011775 sodium fluoride Substances 0.000 claims 1
- 235000013024 sodium fluoride Nutrition 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 208000027140 splenic disease Diseases 0.000 claims 1
- 229960005346 succimer Drugs 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229960004113 tetrofosmin Drugs 0.000 claims 1
- GBECUEIQVRDUKB-UHFFFAOYSA-M thallium monochloride Chemical compound [Tl]Cl GBECUEIQVRDUKB-UHFFFAOYSA-M 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46357403P | 2003-04-17 | 2003-04-17 | |
| PCT/US2004/012084 WO2004093650A2 (en) | 2003-04-17 | 2004-04-19 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006524250A JP2006524250A (ja) | 2006-10-26 |
| JP2006524250A5 true JP2006524250A5 (enExample) | 2007-04-19 |
| JP4633052B2 JP4633052B2 (ja) | 2011-02-16 |
Family
ID=33310796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006513138A Expired - Fee Related JP4633052B2 (ja) | 2003-04-17 | 2004-04-19 | 放射性同位元素で標識したアルカン酸を使用することによる血流および組織への代謝的取込みのモニター法 |
Country Status (9)
| Country | Link |
|---|---|
| US (9) | US7494642B2 (enExample) |
| EP (1) | EP1622602B1 (enExample) |
| JP (1) | JP4633052B2 (enExample) |
| AT (1) | ATE405258T1 (enExample) |
| AU (1) | AU2004232297B2 (enExample) |
| CA (1) | CA2522737C (enExample) |
| DE (1) | DE602004015970D1 (enExample) |
| MX (1) | MXPA05011189A (enExample) |
| WO (1) | WO2004093650A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE353019T1 (de) * | 1995-12-01 | 2007-02-15 | Molecular Insight Pharm Inc | Stereoisomere von fettsäureanalogen zur diagnostischen bildgebung |
| US8909325B2 (en) | 2000-08-21 | 2014-12-09 | Biosensors International Group, Ltd. | Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures |
| US8565860B2 (en) | 2000-08-21 | 2013-10-22 | Biosensors International Group, Ltd. | Radioactive emission detector equipped with a position tracking system |
| US8489176B1 (en) | 2000-08-21 | 2013-07-16 | Spectrum Dynamics Llc | Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures |
| AU2004232297B2 (en) * | 2003-04-17 | 2010-11-04 | The General Hospital Corporation | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid |
| US8586932B2 (en) | 2004-11-09 | 2013-11-19 | Spectrum Dynamics Llc | System and method for radioactive emission measurement |
| US9470801B2 (en) | 2004-01-13 | 2016-10-18 | Spectrum Dynamics Llc | Gating with anatomically varying durations |
| EP1709585B1 (en) | 2004-01-13 | 2020-01-08 | Spectrum Dynamics Medical Limited | Multi-dimensional image reconstruction |
| WO2008010227A2 (en) | 2006-07-19 | 2008-01-24 | Spectrum Dynamics Llc | Imaging protocols |
| US7968851B2 (en) | 2004-01-13 | 2011-06-28 | Spectrum Dynamics Llc | Dynamic spect camera |
| US8571881B2 (en) | 2004-11-09 | 2013-10-29 | Spectrum Dynamics, Llc | Radiopharmaceutical dispensing, administration, and imaging |
| EP1778957A4 (en) | 2004-06-01 | 2015-12-23 | Biosensors Int Group Ltd | OPTIMIZING THE MEASUREMENT OF RADIOACTIVE RADIATION ON SPECIAL BODY STRUCTURES |
| US8423125B2 (en) | 2004-11-09 | 2013-04-16 | Spectrum Dynamics Llc | Radioimaging |
| US8615405B2 (en) | 2004-11-09 | 2013-12-24 | Biosensors International Group, Ltd. | Imaging system customization using data from radiopharmaceutical-associated data carrier |
| EP1827505A4 (en) | 2004-11-09 | 2017-07-12 | Biosensors International Group, Ltd. | Radioimaging |
| US9943274B2 (en) | 2004-11-09 | 2018-04-17 | Spectrum Dynamics Medical Limited | Radioimaging using low dose isotope |
| US9316743B2 (en) | 2004-11-09 | 2016-04-19 | Biosensors International Group, Ltd. | System and method for radioactive emission measurement |
| WO2008059489A2 (en) | 2006-11-13 | 2008-05-22 | Spectrum Dynamics Llc | Radioimaging applications of and novel formulations of teboroxime |
| US8837793B2 (en) | 2005-07-19 | 2014-09-16 | Biosensors International Group, Ltd. | Reconstruction stabilizer and active vision |
| US8644910B2 (en) | 2005-07-19 | 2014-02-04 | Biosensors International Group, Ltd. | Imaging protocols |
| GB0525949D0 (en) | 2005-12-21 | 2006-02-01 | Hammersmith Imanet Ltd | Pet radiotracers |
| JPWO2007080743A1 (ja) * | 2006-01-16 | 2009-06-11 | 国立大学法人 北海道大学 | 検査システムおよび検査方法 |
| US8894974B2 (en) | 2006-05-11 | 2014-11-25 | Spectrum Dynamics Llc | Radiopharmaceuticals for diagnosis and therapy |
| US9275451B2 (en) | 2006-12-20 | 2016-03-01 | Biosensors International Group, Ltd. | Method, a system, and an apparatus for using and processing multidimensional data |
| US8521253B2 (en) | 2007-10-29 | 2013-08-27 | Spectrum Dynamics Llc | Prostate imaging |
| JP2012526129A (ja) * | 2009-05-04 | 2012-10-25 | ワシントン・ユニバーシティ | 脂肪酸代謝および貯蔵を画像化するためのｐｅｔ放射性追跡子 |
| WO2010144876A1 (en) * | 2009-06-12 | 2010-12-16 | University Of Louisville Research Foundation, Inc | Methods to detect cancer in animals |
| US8338788B2 (en) | 2009-07-29 | 2012-12-25 | Spectrum Dynamics Llc | Method and system of optimized volumetric imaging |
| US20110110570A1 (en) * | 2009-11-10 | 2011-05-12 | Avi Bar-Shalev | Apparatus and methods for generating a planar image |
| DE102010010666A1 (de) * | 2010-03-01 | 2011-09-01 | Sven Reske | Diagnose und Therapie von Krebserkrankungen mittels Fettsäuren |
| WO2015032647A1 (en) * | 2013-09-06 | 2015-03-12 | Koninklijke Philips N.V. | Processing apparatus for processing cardiac data |
| BR112019009036A2 (pt) * | 2016-11-08 | 2019-07-16 | Univ California | métodos para a síntese de múltiplas doses de [f-18]fddnp para ajustes clínicos |
| CN108727229B (zh) * | 2017-04-17 | 2021-07-02 | 北京先通国际医药科技股份有限公司 | 一种修饰脂肪酸型pet试剂前体的新工艺路线 |
| CN112638868B (zh) * | 2018-07-20 | 2023-06-20 | 安斯泰来制药株式会社 | 由正电子放射性核素标记的脂肪酸衍生物 |
| JP7652084B2 (ja) * | 2020-01-17 | 2025-03-27 | アステラス製薬株式会社 | 陽電子放出核種で標識された脂肪酸誘導体 |
| CN114700006B (zh) * | 2022-06-07 | 2023-03-24 | 北京先通国际医药科技股份有限公司 | 一种液体组合物的生产设备及其制备方法和用途 |
| CN114732918B (zh) * | 2022-06-10 | 2022-09-13 | 北京先通国际医药科技股份有限公司 | 一种液体组合物的生产设备及其制备方法和用途 |
| CN114736112A (zh) * | 2022-06-14 | 2022-07-12 | 北京先通国际医药科技股份有限公司 | 一种心肌代谢pet显像剂的制备方法及用途 |
| CN114773179B (zh) * | 2022-06-23 | 2022-09-16 | 北京先通国际医药科技股份有限公司 | 一种化合物ⅰ液体组合物的制备方法、及其在心肌代谢pet显像上的用途 |
| CN114796534B (zh) * | 2022-06-23 | 2022-09-16 | 北京先通国际医药科技股份有限公司 | 包含化合物ⅰ的液体组合物、制备方法及用途 |
| CN116199658B (zh) * | 2022-07-22 | 2025-07-22 | 北京先通国际医药科技股份有限公司 | 一种修饰长链脂肪酸型pet试剂前体的合成方法及其用途 |
| CN115181013B (zh) * | 2022-07-22 | 2023-08-08 | 北京先通国际医药科技股份有限公司 | 修饰脂肪酸型pet试剂前体关键中间体的制备方法及其用途 |
| CN116217356A (zh) * | 2022-09-06 | 2023-06-06 | 北京先通国际医药科技股份有限公司 | Pet前体关键中间体的异构体的合成方法及其用途 |
| CN115970012A (zh) * | 2023-03-16 | 2023-04-18 | 北京先通国际医药科技股份有限公司 | 正电子心肌脂肪酸代谢显像剂与正电子18f-fdg心肌葡萄糖显像剂用于pet联合显像的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4119640A (en) * | 1975-07-10 | 1978-10-10 | Union Carbide Corporation | Polymerizable epoxide-modified compositions |
| DE2828623C2 (de) * | 1978-06-29 | 1983-11-17 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Mit radioaktivem Flour markierte C↓1↓↓6↓-bis C↓1↓↓8↓- Fettsäuren, ein Verfahren zu ihrer Herstellung sowie deren Verwendung |
| US4202902A (en) | 1979-03-05 | 1980-05-13 | Shell Oil Company | Lipogenesis control by cyclopropane-carboxylic acids, esters and amides |
| US4524059A (en) * | 1983-01-28 | 1985-06-18 | The General Hospital Corporation | Fatty acid analogs |
| US4933365A (en) * | 1989-01-25 | 1990-06-12 | American Home Products Corporation | Phospholipase A2 inhibitors |
| DE4012405C1 (en) * | 1990-04-19 | 1991-08-14 | Forschungszentrum Juelich Gmbh, 5170 Juelich, De | Radioisotope labelled oxiranyl carboxylic acid derivs. prodn. - by nucleophilic replacement of corresp. bromo or iodo substits. with radioactive alkali halide(s) in polar medium |
| ATE353019T1 (de) * | 1995-12-01 | 2007-02-15 | Molecular Insight Pharm Inc | Stereoisomere von fettsäureanalogen zur diagnostischen bildgebung |
| IT1295658B1 (it) * | 1997-09-29 | 1999-05-24 | Menarini Ricerche Spa | Composizioni farmaceutiche contenenti acido ricinoleico e loro uso per la terapia antifiammatoria ed analgesica |
| DE60030270T2 (de) | 1999-04-14 | 2007-08-30 | Molecular Insight Pharmaceuticals, Inc., Cambridge | Fettsaure analoge zur diagnose von kranzarterie erkrankungen |
| WO2004092184A1 (de) * | 2003-04-12 | 2004-10-28 | Forschungszentrum Rossendorf E.V. | Technetiummarkierte fettsäuren und deren verwendung für die myokarddiagnostik sowie verfahren zur herstellung der technetiummarkierten fettsäuren |
| AU2004232297B2 (en) | 2003-04-17 | 2010-11-04 | The General Hospital Corporation | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid |
| EP2274725A1 (en) * | 2008-04-04 | 2011-01-19 | Advanced Micro Devices, Inc. | Filtering method and apparatus for anti-aliasing |
-
2004
- 2004-04-19 AU AU2004232297A patent/AU2004232297B2/en not_active Ceased
- 2004-04-19 WO PCT/US2004/012084 patent/WO2004093650A2/en not_active Ceased
- 2004-04-19 CA CA2522737A patent/CA2522737C/en not_active Expired - Fee Related
- 2004-04-19 MX MXPA05011189A patent/MXPA05011189A/es active IP Right Grant
- 2004-04-19 DE DE602004015970T patent/DE602004015970D1/de not_active Expired - Lifetime
- 2004-04-19 EP EP04760019A patent/EP1622602B1/en not_active Expired - Lifetime
- 2004-04-19 US US10/827,054 patent/US7494642B2/en not_active Expired - Fee Related
- 2004-04-19 AT AT04760019T patent/ATE405258T1/de not_active IP Right Cessation
- 2004-04-19 JP JP2006513138A patent/JP4633052B2/ja not_active Expired - Fee Related
-
2007
- 2007-10-10 US US11/973,810 patent/US20080214853A1/en not_active Abandoned
- 2007-10-11 US US11/973,922 patent/US8309053B2/en not_active Expired - Fee Related
- 2007-10-11 US US11/973,926 patent/US20080214851A1/en not_active Abandoned
- 2007-10-11 US US11/973,921 patent/US20080095702A1/en not_active Abandoned
- 2007-10-11 US US11/974,139 patent/US7790142B2/en not_active Expired - Lifetime
- 2007-10-11 US US11/973,925 patent/US20080213178A1/en not_active Abandoned
-
2009
- 2009-02-23 US US12/391,250 patent/US8268291B2/en not_active Expired - Fee Related
-
2012
- 2012-08-27 US US13/595,546 patent/US8871179B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006524250A5 (enExample) | ||
| Herrero Álvarez et al. | Recent advances in radiometals for combined imaging and therapy in cancer | |
| JP4633052B2 (ja) | 放射性同位元素で標識したアルカン酸を使用することによる血流および組織への代謝的取込みのモニター法 | |
| JP2020203893A (ja) | Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤 | |
| Poty et al. | The inverse electron-demand Diels–Alder reaction as a new methodology for the synthesis of 225Ac-labelled radioimmunoconjugates | |
| CN112770785A (zh) | 前列腺特异性膜抗原(psma)的标记抑制剂，其作为显像剂和药剂用于治疗表达psma的癌症的用途 | |
| Tsiapa et al. | Biological evaluation of an ornithine-modified 99mTc-labeled RGD peptide as an angiogenesis imaging agent | |
| Liu | Ether and crown ether-containing cationic 99m Tc complexes useful as radiopharmaceuticals for heart imaging | |
| Ahmed et al. | Diagnostic modalities and radiopharmaceuticals with particular importance of technetium-99m (99mTc) | |
| Liu et al. | Evaluation of novel cationic 99mTc-nitrido complexes as radiopharmaceuticals for heart imaging: improving liver clearance with crown ether groups | |
| JP3015970B2 (ja) | 遷移金属の窒化物錯体を含んでいる、心臓への向性を特に有する放射性医薬製品およびその製造方法 | |
| Kaizuka et al. | Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics | |
| Kim et al. | Tc-99m-N-MPO: novel cationic Tc-99m radiotracer for myocardial perfusion imaging | |
| Ito et al. | PET and planar imaging of tumor hypoxia with labeled metronidazole | |
| Kimura et al. | Development of 99mTc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging | |
| Kim et al. | Mechanism for myocardial localization and rapid liver clearance of Tc-99m-N-MPO: a new perfusion radiotracer for heart imaging | |
| JP7036543B2 (ja) | 腫瘍イメージング剤、及びホウ素中性子捕捉療法用腫瘍治療剤 | |
| Kim et al. | Minimizing liver uptake of cationic 99mTc radiotracers with ether and crown ether functional groups | |
| Fang et al. | New 99mTc radiotracers for myocardial perfusion imaging by SPECT | |
| Kong et al. | Development of 99mTc-EC-tyrosine for early detection of breast cancer tumor response to the anticancer drug melphalan | |
| Yang et al. | Impact of boronate capping groups on biological characteristics of novel 99mTc (III) complexes [99mTcCl (CDO)(CDOH) 2B-R](CDOH2= cyclohexanedione dioxime) | |
| JP6085810B2 (ja) | 放射性医薬及び医薬キット | |
| JP6609868B2 (ja) | 放射性ハロゲン標識ピリド［１，２−ａ］ベンゾイミダゾール誘導体化合物 | |
| US7556794B2 (en) | Pendant fatty acid imaging agents | |
| JP2025503096A (ja) | がんの処置および撮像のための複合体 |